Karyopharm Therapeutics Inc (KPTI)
1.09
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
1.095
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics Net Income (Quarterly): -41.84M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -41.84M |
| September 30, 2023 | -34.51M |
| June 30, 2023 | -32.63M |
| March 31, 2023 | -34.13M |
| December 31, 2022 | -38.51M |
| September 30, 2022 | -36.32M |
| June 30, 2022 | -49.06M |
| March 31, 2022 | -41.40M |
| December 31, 2021 | 38.72M |
| September 30, 2021 | -51.81M |
| June 30, 2021 | -53.58M |
| March 31, 2021 | -57.41M |
| December 31, 2020 | -43.42M |
| September 30, 2020 | -53.50M |
| June 30, 2020 | -46.43M |
| March 31, 2020 | -52.93M |
| December 31, 2019 | -48.65M |
| September 30, 2019 | -41.37M |
| June 30, 2019 | -43.42M |
| March 31, 2019 | -66.16M |
| December 31, 2018 | -58.21M |
| September 30, 2018 | -48.08M |
| June 30, 2018 | -33.66M |
| Date | Value |
|---|---|
| March 31, 2018 | -38.46M |
| December 31, 2017 | -39.04M |
| September 30, 2017 | -30.64M |
| June 30, 2017 | -29.39M |
| March 31, 2017 | -29.92M |
| December 31, 2016 | -26.94M |
| September 30, 2016 | -25.42M |
| June 30, 2016 | -30.16M |
| March 31, 2016 | -27.06M |
| December 31, 2015 | -29.05M |
| September 30, 2015 | -30.37M |
| June 30, 2015 | -32.70M |
| March 31, 2015 | -26.07M |
| December 31, 2014 | -25.93M |
| September 30, 2014 | -19.72M |
| June 30, 2014 | -16.43M |
| March 31, 2014 | -13.69M |
| December 31, 2013 | -12.15M |
| September 30, 2013 | -9.321M |
| June 30, 2013 | -6.869M |
| March 31, 2013 | -5.611M |
| December 31, 2012 | -4.238M |
| September 30, 2012 | -3.635M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-57.41M
Minimum
Mar 2021
38.72M
Maximum
Dec 2021
-40.11M
Average
-43.42M
Median
Jun 2019
Net Income (Quarterly) Benchmarks
| Geron Corp | -51.97M |
| Arbutus Biopharma Corp | -19.31M |
| Verastem Inc | -27.37M |
| Actinium Pharmaceuticals Inc | -9.324M |
| Chimerix Inc | -18.16M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 33.75M |
| Total Expenses (Quarterly) | 71.56M |
| EPS Diluted (Quarterly) | -0.36 |
| Enterprise Value | 104.90M |
| Gross Profit Margin (Quarterly) | 95.60% |
| Profit Margin (Quarterly) | -124.0% |
| Earnings Yield | -114.2% |
| Normalized Earnings Yield | -113.99 |